Yuhan sold technology YH1885 to SB at a hundred million dollar.

Published: 2000-10-05 10:58:00

Updated: 2000-10-05 10:58:00

Yuhan has developed a new anti-peptic ulcer agent, YH1885 ( a proton-pump channel inhibitor) as one of the government's G7 projects and sold it out to Smithkline Beecham at U$100 million of its royalty. Two parties made an agreement on Oct. 2 at the Ministry of Science and Technology at a lump-su...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK